** Shares of Simcere Pharmaceutical Group Ltd 2096.HK jump 5.5% to HK$8.07, their biggest intraday pct gain since February 18
** Stock on course for a third consecutive session of gains, if current trend holds
** Simcere Pharmaceutical says its anti-tumor drug candidate - SIM0686 - has obtained a Clinical Trial Approval, issued by China's National Medical Products Administration (NMPA)
** SIM0686 is an FGFR2b Antibody-Drug Conjugate for treatment of gastric cancer and lung cancer
** Hong Kong's healthcare index .HSCIH rises 2.1%, Hang Seng Index .HSI rises 1.8%
** Stock up 7.8% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.